Nurse Practitioner in Wilder, KY Accepting Medicare
4 Nurse Practitioner nurses found. Showing 1 - 4
 Nichole B Haley, MSN, APRN, CPNP-PC Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1016 Town Drive, Wilder, KY 41076 Phone: 859-441-7600 Fax: 859-441-7144 |
Jennifer Lynn Hawkins, Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 519 Licking Pike, Wilder, KY 41071 Phone: 859-572-0400 |
Mrs. Kimberly Michelle Witte, ARNP CS BC Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 519 Licking Pike, Wilder, KY 41071 Phone: 859-572-0400 Fax: 859-442-3363 |
Mrs. Lonna Louise Larger, MSN, PMHNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Accepting Medicare Assignments Practice Location: 519 Licking Pike, Wilder, KY 41071 Phone: 859-572-0400 Fax: 859-442-3363 |
News Archive
Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors
Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.
Novavax, Xcellerex enter into collaboration to accelerate the development of Novavax's 2009 H1N1 vaccine
Novavax, Inc. and Xcellerex, Inc. have entered into a strategic collaboration to accelerate the development of Novavax's vaccine manufacturing process to commercial scale and begin immediate production of Novavax's novel 2009 H1N1 influenza vaccine for potential commercial sale.
Research opens door to new direction of PAH treatment
The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.
Understanding the causal relationships between diabetes, obesity and NAFLD
Diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) are all common diseases that can lead to serious health implications.
Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients
Aradigm Corporation today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind, placebo-controlled Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE) under a U.S. IND. This orphan disease indication is a chronic, severe respiratory disease and there are currently no approved treatments for this disease in the U.S.
› Verified 6 days ago